Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRUCK: Ixekizumab, Aldesleukin, or Colchicine for Severe COVID-19
NCT04724629Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ixekizumab, aldesleukin, colchicine in coronavirus disease 2019 (COVID-19), sponsored by Universidade de São Paulo. Started Jan 2021; status: completed.
02
Drugs
ixekizumabaldesleukincolchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04724629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724629.